Solution Conformations of Zika NS2B-NS3pro and Its Inhibition by Natural Products from Edible Plants
Overview
Affiliations
The recent Zika viral (ZIKV) epidemic has been associated with severe neurological pathologies such as neonatal microcephaly and Guillain-Barre syndrome but unfortunately no vaccine or medication is effectively available yet. Zika NS2B-NS3pro is essential for the proteolysis of the viral polyprotein and thereby viral replication. Thus NS2B-NS3pro represents an attractive target for anti-Zika drug discovery/design. Here, we have characterized the solution conformations and catalytic parameters of both linked and unlinked Zika NS2B-NS3pro complexes and found that the unlinked complex manifested well-dispersed NMR spectra. Subsequently with selective isotope-labeling using NMR spectroscopy, we demonstrated that C-terminal residues (R73-K100) of NS2B is highly disordered without any stable tertiary and secondary structures in the Zika NS2B-NS3pro complex in the free state. Upon binding to the well-characterized serine protease inhibitor, bovine pancreatic trypsin inhibitor (BPTI), only the extreme C-terminal residues (L86-K100) remain disordered. Additionally, we have identified five flavonoids and one natural phenol rich in edible plants including fruits and vegetables, which inhibit Zika NS2B-NS3pro in a non-competitive mode, with Ki ranging from 770 nM for Myricetin to 34.02 μM for Apigenin. Molecular docking showed that they all bind to a pocket on the back of the active site and their structure-activity relationship was elucidated. Our study provides valuable insights into the solution conformation of Zika NS2B-NS3pro and further deciphers its susceptibility towards allosteric inhibition by natural products. As these natural product inhibitors fundamentally differ from the currently-known active site inhibitors in terms of both inhibitory mode and chemical scaffold, our finding might open a new avenue for development of better allosteric inhibitors to fight ZIKV infection.
A Comprehensive Review of the Development and Therapeutic Use of Antivirals in Flavivirus Infection.
Tripathi A, Chauhan S, Khasa R Viruses. 2025; 17(1).
PMID: 39861863 PMC: 11769230. DOI: 10.3390/v17010074.
An Overview of Zika Virus and Zika Virus Induced Neuropathies.
Wahaab A, Mustafa B, Hameed M, Batool H, Tran Nguyen Minh H, Tawaab A Int J Mol Sci. 2025; 26(1.
PMID: 39795906 PMC: 11719530. DOI: 10.3390/ijms26010047.
Recent advances in the study of zika virus structure, drug targets, and inhibitors.
Feng Y Front Pharmacol. 2024; 15:1418516.
PMID: 39011504 PMC: 11246971. DOI: 10.3389/fphar.2024.1418516.
The search for an antiviral lead molecule to combat the neglected emerging Oropouche virus.
Peinado R, Saivish M, de Lima Menezes G, Fulco U, da Silva R, Korostov K Curr Res Microb Sci. 2024; 6:100238.
PMID: 38745914 PMC: 11090880. DOI: 10.1016/j.crmicr.2024.100238.
A Non-Active-Site Inhibitor with Selectivity for Zika Virus NS2B-NS3 Protease.
Cruz K, Hill Eron M, Makhaik S, Savinov S, Hardy J ACS Infect Dis. 2024; 10(2):412-425.
PMID: 38265226 PMC: 11099878. DOI: 10.1021/acsinfecdis.3c00330.